CAR-γδ T Cells
Hematological malignancies (e.g., Acute Myeloid Leukemia)
Key Facts
About CytoMed Therapeutics
CytoMed Therapeutics is focused on translating innovative immunology research into transformative cancer treatments, primarily through its two core platforms: allogeneic γδ T cell therapies and CAR-engineered γδ T cells. The company's lead candidate, CTM-N2D, is an off-the-shelf, donor-derived γδ T cell product in Phase 1 development for various solid tumors. With a NASDAQ listing and a strategic base in Singapore's biotech hub, CytoMed aims to address significant unmet needs in oncology by developing safer and more accessible cell therapies.
View full company profileAbout CytoMed Therapeutics
CytoMed Therapeutics is focused on translating innovative immunology research into transformative cancer treatments, primarily through its two core platforms: allogeneic γδ T cell therapies and CAR-engineered γδ T cells. The company's lead candidate, CTM-N2D, is an off-the-shelf, donor-derived γδ T cell product in Phase 1 development for various solid tumors. With a NASDAQ listing and a strategic base in Singapore's biotech hub, CytoMed aims to address significant unmet needs in oncology by developing safer and more accessible cell therapies.
View full company profile